血必净注射液治疗新型冠状病毒肺炎疑似病例24例临床研究

Clinical effect of Xuebijing injection in treatment of patients suspected of coronavirus disease 2019:An analysis of 24 cases

目的:研究血必净注射液治疗新型冠状病毒肺炎(COVID-19)疑似病例的临床疗效。方法:将COVID-19疑似病例48例随机分为治疗组和对照组,每组各24例。对照组采用西医常规治疗,治疗组在对照组的基础上加用血必净注射液治疗。观察比较2组治疗前后体温、心率、C反应蛋白(CRP)、红细胞沉降率(ESR)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)的变化,评定临床疗效,记录不良反应。结果:总有效率治疗组为95.8%(23/24),对照组为83.3%(20/24),2组比较,差异有统计学意义(P<0.05)。2组体温、心率、CRP、ESR、TNF-α、IL-6治疗前后组内比较及治疗后组间比较,差异均有统计学意义(P<0.05)。2组治疗过程中均无不良反应发生。结论:西医常规疗法联合血必净注射液治疗COVID-19疑似病例临床疗效较佳,可资借鉴。

Objective:To investigate the clinical effect of Xuebijing injection in the treatment of patients suspected of coronavirus disease 2019(COVID-19).Methods:A total of 48 patients suspected of COVID-19 were randomly divided into treatment group and control group,with 24 patients in each group.The patients in the control group were given conventional Western medicine treatment,and those in the treatment group were given Xuebijing injection in addition to the treatment in the control group.The two groups were compared in terms of the changes in body temperature,heart rate,C-reactive protein(CRP),erythrocyte sedimentation rate(ESR),tumor necrosis factor-α(TNF-α),and interleukin-6(IL-6)after treatment;clinical outcome was evaluated,and adverse reactions were recorded.Results:There was a significant difference in overall response rate between the treatment group and the control group[95.8%(23/24)vs 83.3%(20/24),P<0.05].After treatment,both groups had significant changes in body temperature,heart rate,CRP,ESR,TNF-α,and IL-6,and there were significant differences in these indices between the two groups(P<0.05).No adverse reaction was observed during treatment.Conclusion:Conventional Western medicine treatment combined with Xuebijing injection has a good clinical effect in the treatment of patients suspected of COVID-19 and thus holds promise for clinical application.